CDK7 Inhibition Synergizes with Topoisomerase I Inhibition in Small Cell Lung Cancer Cells by Inducing Ubiquitin-Mediated Proteolysis of RNA Polymerase II

Overview

Journal Mol Cancer Ther

Date 2022 Jul 13

PMID 35830858

Authors

Yilun Sun

Yang Zhang

Christopher W Schultz

Yves Pommier

Anish Thomas

Affiliations

Soon will be listed here.

Abstract

Small cell lung cancers (SCLC) are highly aggressive, and currently there are no available targeted therapies. To identify clinically actionable drug combinations, we analyzed our previously reported chemogenomics screens and identified a synergistically cytotoxic combination of the topoisomerase I (TOP1) inhibitor topotecan and cycle-dependent kinase 7 (CDK7) inhibitor THZ1. Topotecan causes cell death by generating TOP1-induced DNA breaks and DNA-protein cross-links (TOP1-DPC) that require proteolysis by the ubiquitin-proteasome pathway for their repair. We find that inhibition of the transcriptional kinase CDK7 by THZ1 induces ubiquitin-mediated proteasomal degradation of RNA polymerase II and prevents the proteasomal degradation of TOP1-DPCs. We provide a mechanistic basis for combinatorial targeting of transcription using selective inhibitors of CDK7 and TOP1 in clinical trials to advance SCLC therapeutics.

Citing Articles

Genomic alterations and transcriptional phenotypes in circulating free DNA and matched metastatic tumor.

Takahashi N, Pongor L, Agrawal S, Shtumpf M, Gurjar A, Rajapakse V Genome Med. 2025; 17(1):15.

PMID: 40001151 PMC: 11863907. DOI: 10.1186/s13073-025-01438-4.

CRL3 ubiquitin ligase and Integrator phosphatase form parallel mechanisms to control early stages of RNA Pol II transcription.

Cacioppo R, Gillis A, Shlamovitz I, Zeller A, Castiblanco D, Crisp A Mol Cell. 2024; 84(24):4808-4823.e13.

PMID: 39667934 PMC: 7617427. DOI: 10.1016/j.molcel.2024.11.024.

Actionable Driver Events in Small Cell Lung Cancer.

Gutierrez M, Zamora I, Freeman M, Encio I, Rotinen M Int J Mol Sci. 2024; 25(1).

PMID: 38203275 PMC: 10778712. DOI: 10.3390/ijms25010105.

Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex.

Sun Y, Baechler S, Zhang X, Kumar S, Factor V, Arakawa Y Nat Commun. 2023; 14(1):3762.

PMID: 37353483 PMC: 10290057. DOI: 10.1038/s41467-023-39374-9.

Requirements for MRN endonuclease processing of topoisomerase II-mediated DNA damage in mammalian cells.

Sun Y, Soans E, Mishina M, Petricci E, Pommier Y, Nitiss K Front Mol Biosci. 2022; 9:1007064.

PMID: 36213114 PMC: 9537633. DOI: 10.3389/fmolb.2022.1007064.

References

Coussy F, El-Botty R, Chateau-Joubert S, Dahmani A, Montaudon E, Leboucher S . BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Sci Transl Med. 2020; 12(531). PMC: 8662740. DOI: 10.1126/scitranslmed.aax2625. View

Pommier Y, Nussenzweig A, Takeda S, Austin C . Human topoisomerases and their roles in genome stability and organization. Nat Rev Mol Cell Biol. 2022; 23(6):407-427. PMC: 8883456. DOI: 10.1038/s41580-022-00452-3. View

Interthal H, Chen H, Champoux J . Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages. J Biol Chem. 2005; 280(43):36518-28. PMC: 1351008. DOI: 10.1074/jbc.M508898200. View

Christensen C, Kwiatkowski N, Abraham B, Carretero J, Al-Shahrour F, Zhang T . Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 2014; 26(6):909-922. PMC: 4261156. DOI: 10.1016/j.ccell.2014.10.019. View

Thomas A, Pommier Y . Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res. 2019; 25(22):6581-6589. PMC: 6858945. DOI: 10.1158/1078-0432.CCR-19-1089. View

Jahchan N, Lim J, Bola B, Morris K, Seitz G, Tran K . Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. Cell Rep. 2016; 16(3):644-56. PMC: 4956576. DOI: 10.1016/j.celrep.2016.06.021. View

Sun Y, Saha S, Wang W, Saha L, Huang S, Pommier Y . Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC). DNA Repair (Amst). 2020; 89:102837. PMC: 7188568. DOI: 10.1016/j.dnarep.2020.102837. View

Desai S, Li T, Rubin E, Liu L . Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 2001; 61(15):5926-32. View

Fisher R . Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery. Transcription. 2018; 10(2):47-56. PMC: 6602562. DOI: 10.1080/21541264.2018.1553483. View

10.

Fisher R . Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci. 2005; 118(Pt 22):5171-80. DOI: 10.1242/jcs.02718. View

11.

Desai S, Liu L, DArpa P . Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem. 1997; 272(39):24159-64. DOI: 10.1074/jbc.272.39.24159. View

12.

Sordet O, Larochelle S, Nicolas E, Stevens E, Zhang C, Shokat K . Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I. J Mol Biol. 2008; 381(3):540-9. PMC: 2754794. DOI: 10.1016/j.jmb.2008.06.028. View

13.

Krastev D, Li S, Sun Y, Wicks A, Hoslett G, Weekes D . The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin. Nat Cell Biol. 2022; 24(1):62-73. PMC: 8760077. DOI: 10.1038/s41556-021-00807-6. View

14.

Ljungman M, HANAWALT P . The anti-cancer drug camptothecin inhibits elongation but stimulates initiation of RNA polymerase II transcription. Carcinogenesis. 1996; 17(1):31-5. DOI: 10.1093/carcin/17.1.31. View

15.

Tlemsani C, Pongor L, Elloumi F, Girard L, Huffman K, Roper N . SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. Cell Rep. 2020; 33(3):108296. PMC: 7643325. DOI: 10.1016/j.celrep.2020.108296. View

16.

Galbraith M, Bender H, Espinosa J . Therapeutic targeting of transcriptional cyclin-dependent kinases. Transcription. 2018; 10(2):118-136. PMC: 6602565. DOI: 10.1080/21541264.2018.1539615. View

17.

Yankulov K, Yamashita K, Roy R, Egly J, Bentley D . The transcriptional elongation inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase. J Biol Chem. 1995; 270(41):23922-5. DOI: 10.1074/jbc.270.41.23922. View

18.

Thomas A, Takahashi N, Rajapakse V, Zhang X, Sun Y, Ceribelli M . Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer Cell. 2021; 39(4):566-579.e7. PMC: 8048383. DOI: 10.1016/j.ccell.2021.02.014. View

19.

Takahashi N, Kim S, Schultz C, Rajapakse V, Zhang Y, Redon C . Replication stress defines distinct molecular subtypes across cancers. Cancer Res Commun. 2022; 2(6):503-517. PMC: 9648410. DOI: 10.1158/2767-9764.crc-22-0168. View

20.

Rudin C, Hann C, Garon E, Ribeiro de Oliveira M, Bonomi P, Camidge D . Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012; 18(11):3163-9. PMC: 3715059. DOI: 10.1158/1078-0432.CCR-11-3090. View